Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma
暂无分享,去创建一个
P. Wen | R. Jain | T. Cloughesy | D. Schiff | E. Lee | E. Gerstner | D. Reardon | A. Lassman | A. Muzikansky | D. Duda | Sarah C. Gaffey | S. Yunus | Jennifer Bruno | Jennifer Barrs | Daniel G. Duda